| dc.contributor.author | De Giorgi, Riccardo | |
| dc.date.accessioned | 2019-01-04T11:12:30Z | |
| dc.date.available | 2019-01-04T11:12:30Z | |
| dc.date.issued | 2018-12-17 | |
| dc.identifier.citation | Riccardo de Giorgi. Vortioxetine for depression: the evidence for its current use in the UK: COMMENTARY ON… COCHRANE CORNER. BJPsych Advances Vol 25. 1 2019 p3-6. | en |
| dc.identifier.issn | 2056-4686 | |
| dc.identifier.uri | https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/157 | |
| dc.description | The article attached to this record is the Author(s) pre-/post- print version only. NOTE: this is not the version published in BJPsych Advances. Minor changes may have been made for publication. Eligible users can access the full text via NHS OpenAthens (login required) | |
| dc.description.abstract | The pharmacological treatment of depression is often hampered by side-effects and unsatisfactory response to treatment. Vortioxetine is one of the newest antidepressants on the market, purportedly with a different mechanism of action compared with other antidepressants. This month's Cochrane Corner review examines the evidence available for the use of vortioxetine as a first-line treatment for depression in adults. This commentary puts the Cochrane review's findings into their clinical context and revises them in view of earlier and later studies | en |
| dc.description.uri | https://doi.org/10.1192/bja.2018.62 | |
| dc.language.iso | en | en |
| dc.subject | Depressive Disorders | en |
| dc.subject | Antidepressant Drugs | en |
| dc.title | Vortioxetine for depression: the evidence for its current use in the UK: COMMENTARY ON… COCHRANE CORNER | en |
| dc.type | PrePrint | en |
